Your browser doesn't support javascript.
loading
GREENER Pharmaceuticals for More Sustainable Healthcare.
Moermond, Caroline T A; Puhlmann, Neele; Brown, A Ross; Owen, Stewart F; Ryan, Jim; Snape, Jason; Venhuis, Bastiaan J; Kümmerer, Klaus.
Afiliação
  • Moermond CTA; Centre for Safety of Substances and Products (VSP), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands.
  • Puhlmann N; Institut für Nachhaltige Chemie und Umweltchemie, Leuphana Universität Lüneburg, Universitätsallee 1, C13.205, 21335 Lüneburg, Germany.
  • Brown AR; Biosciences, College of Life and Environmental Sciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, Devon EX4 4QD, U.K.
  • Owen SF; AstraZeneca, Global Sustainability, Silk Road, Macclesfield, Cheshire SK10 2NA, U.K.
  • Ryan J; GSK, Environment, Health & Safety, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.
  • Snape J; AstraZeneca, Global Sustainability, Silk Road, Macclesfield, Cheshire SK10 2NA, U.K.
  • Venhuis BJ; Centre for Health Protection (GZB), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands.
  • Kümmerer K; Institut für Nachhaltige Chemie, Leuphana Universität Lüneburg, Universitätsallee, 1/C13.311b, 21335 Lüneburg, Germany.
Environ Sci Technol Lett ; 9(9): 699-705, 2022 Sep 13.
Article em En | MEDLINE | ID: mdl-36118957
ABSTRACT
Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article